🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

522 results for “therapy” Clear

  1. AUTO1, MabThera 500 mg concentrate for solution for infusion, AUTO4, MabThera 100 mg concentrate for solution for infusion

    Autolus GmbH

    Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.

    phase 2 small molecule active

    1 trial

  2. AdaptNK –Cell Therapy for High-risk Myeloid Disease

    The George Institute

    Relapsed and/or refractory AML or MDS

    phase 2 other active

    1 trial

  3. Apatinib

    The First People's Hospital of Lianyungang

    Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  4. Apheresis and Bridging Therapy

    The First People's Hospital of Lianyungang

    Large B-cell Lymphoma

    phase 2 other completed

    1 trial

  5. Autologous hematopoietic stem cell infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prolonged Cytopenia Following CAR-T Therapy

    phase 2 mab active

    1 trial

  6. Avatrombopag

    Hospital Authority, Hong Kong

    Chemotherapy-induced Thrombocytopenia

    phase 2 small molecule active

    1 trial

  7. B-MAD chemotherapy

    Takeda

    Extranodal NK/T-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  8. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Urinary Tract Infection Bacterial

    phase 2 mab terminated

    1 trial

  9. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Osteomyelitis

    phase 2 mab terminated

    1 trial

  10. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

    phase 2 other terminated

    1 trial

  11. Behavioral Couples Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    phase 2 other completed

    1 trial

  12. Bispecific antibody-based combined with CAR-T cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  13. Blinatumomab plus Reduced-dose Chemotherapy

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  14. Buprenorphine and Outpatient Parenteral Antibiotic Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Use

    phase 2 small molecule completed

    1 trial

  15. CAPECITABINE, CAPECITABINE, PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.

    phase 2 small molecule active

    1 trial

  16. CAPECITABINE, OXALIPLATIN, FLUOROURACIL, CAPECITABINE, FOLINIC ACID

    Ningbo Cancer Hospital

    Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication

    phase 2 small molecule active

    1 trial

  17. CAR T-cell therapy

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia With Failed Remission

    phase 2 mab active

    1 trial

  18. CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance

    Daihong Liu

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

    phase 2 small molecule active

    1 trial

  19. CARBOPLATIN , PACLITAXEL , NP137, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.

    phase 2 small molecule active

    1 trial

  20. CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy

    Tour Hekla

    Pneumocystis pneumonia

    phase 2 other active

    1 trial

  21. Cadonilimab

    Second Affiliated Hospital of Soochow University

    Immunotherapy

    phase 2 small molecule active

    1 trial

  22. Cadonilimab

    The First People's Hospital of Lianyungang

    Immunotherapy

    phase 2 small molecule active

    1 trial

  23. Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a phase I trial

    Pari Pharma GmbH

    Inclusion Body Myositis

    phase 2 other active

    1 trial

  24. Cesium-131 brachytherapy

    GT Biopharma

    Recurrent Brain Metastases

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources